Centrexion
OverviewSuggest Edit
Centrexion Therapeutics is focused on developing new therapies for moderate to severe chronic pain that address the safety and efficacy gaps in the current treatment paradigm.
We aim to relieve the suffering associated with chronic pain by creating treatments that address the safety and efficacy gaps in the current treatment paradigm.
| Type | Public | |
| Founded | 2013 | |
| HQ | Boston, MA, US | Map |
| Website | centrexion.com |
Recent NewsAll News
- Centrexion Therapeutics Raises $40.5 Million and Adds Lilly and Exome Asset Management as New Investors
- Centrexion Therapeutics to Announce CNTX-4975 Trial Results at the European League Against Rheumatism’s (EULAR) 2019 Annual European Congress of Rheumatology
- Centrexion Therapeutics Announces Completion of Patient Enrollment in Pivotal Clinical Trial of Repeat Doses of CNTX-4975 in Patients with Moderate to Severe Osteoarthritis Knee Pain
- Lilly Announces Licensing Agreement for Non-Opioid Pain Asset from Centrexion Therapeutics
Key People/Management at Centrexion
Jeffrey B. Kindler
CEO
James N. Campbell
President, Chief Scientific Officer
Randall Stevens
Chief Medical Officer
Mike Ward
Chief Financial Officer
Kimberly Guedes
Vice President, Clinical Operations
Sol Barer
Chairman
Centrexion Office Locations
Centrexion has offices in Boston and Baltimore
Boston, MA, US (HQ)
200 State St 6th Floor
Baltimore, MD, US
509 S Exeter St #202
Centrexion Financials and Metrics
Centrexion Revenue
| USD | |
|---|---|
Net income (FY, 2017) | (24.7m) |
EBIT (FY, 2017) | (24.1m) |
Cash (30-Sept-2018) | 42.1m |
Annual
| USD | FY, 2016 | FY, 2017 |
|---|---|---|
Cash | 16.2m | 60.7m |
Prepaid Expenses | 827.0k | 665.0k |
Current Assets | 17.1m | 61.3m |
PP&E | 60.0k | 29.0k |
Quarterly
| USD | Q3, 2018 |
|---|---|
Cash | 42.1m |
Prepaid Expenses | 3.8m |
Current Assets | 45.9m |
PP&E | 23.0k |
Annual
| USD | FY, 2016 | FY, 2017 |
|---|---|---|
Net Income | (37.7m) | (24.6m) |
Depreciation and Amortization | 36.0k | 21.0k |
Accounts Payable | 1.0m | 358.0k |
Cash From Operating Activities | (30.6m) | (22.3m) |
Quarterly
| USD | Q3, 2018 | Q3, 2019 |
|---|---|---|
Net Income | (19.5m) | (25.3m) |
Depreciation and Amortization | 19.0k | 6.0k |
Accounts Payable | 1.9m | 1.2m |
Cash From Operating Activities | (16.8m) | (24.3m) |
| USD | FY, 2016 |
|---|---|
Financial Leverage | 1.8 x |
Centrexion Cybersecurity Score
Centrexion Online and Social Media Presence
243 Twitter followers
Centrexion has 243 Twitter Followers. The number of followers has increased 0.9% month over month and increased 1.3% quarter over quarter
Centrexion's Trends
Centrexion News and Updates
October 29, 2020
Centrexion Therapeutics Raises $40.5 Million and Adds Lilly and Exome Asset Management as New Investors
BOSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Centrexion Therapeutics Corporation, a biotechnology company focused on developing and commercializing non-opioid, non-addictive chronic pain drugs and in-licensing undervalued mid-stage drug candidates across multiple target therapeutic areas, today annou…
June 11, 2019
Centrexion Therapeutics to Announce CNTX-4975 Trial Results at the European League Against Rheumatism’s (EULAR) 2019 Annual European Congress of Rheumatology
BOSTON, June 11, 2019 (GLOBE NEWSWIRE) -- Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-addictive therapeutics for the treatment of chronic pain, today announced that it will report data from two clinical studies of CNTX-4975, including an assessment of the c…
June 05, 2019
Centrexion Therapeutics Announces Completion of Patient Enrollment in Pivotal Clinical Trial of Repeat Doses of CNTX-4975 in Patients with Moderate to Severe Osteoarthritis Knee Pain
BOSTON, June 05, 2019 (GLOBE NEWSWIRE) -- Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-addictive therapeutics for the treatment of chronic pain, today announced completion of patient enrollment in its second pivotal trial, VICTORY-2, a randomized, double-bli…
May 28, 2019
Lilly Announces Licensing Agreement for Non-Opioid Pain Asset from Centrexion Therapeutics
INDIANAPOLIS, May 28, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a license agreement to acquire the exclusive worldwide rights for CNTX-0290 from Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-addictive therapeutics for the ...
March 07, 2019
Centrexion Therapeutics Announces CNTX-4975 Preclinical and Clinical Data Presentations at the 35th Annual American Academy of Pain Medicine Meeting
Company will present two posters on CNTX-4975 for treatment of moderate to severe knee osteoarthritis pain;pharmacological data from preclinical and Phase 1 and 2 clinical trials describing the mechanism of action; and efficacy,safety and pharmacokinetic profile from late-stage clinical trials
December 05, 2018
Centrexion Therapeutics Announces Completion of Patient Enrollment in Pivotal Phase 3 Clinical Trial of CNTX-4975 for the Treatment of Moderate to Severe Knee Osteoarthritis Pain
BOSTON, Dec. 05, 2018 (GLOBE NEWSWIRE) -- Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-addictive therapeutics for the treatment of chronic pain, today announced completion of patient enrollment ahead of schedule in its pivotal Phase 3 VICTORY-1 trial, a rand…
Centrexion Blogs
December 03, 2019
Centrexion Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Lead Pipeline Candidate CNTX-4975
The post Centrexion Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Lead Pipeline Candidate CNTX-4975 appeared first on Centrexion.
November 08, 2019
Centrexion Therapeutics Announces CNTX-4975 Data Presentations at the 2019 American College of Rheumatology Annual Meeting and the 2019 American Academy of Physical Medicine and Rehabilitation Annual Assembly
The post Centrexion Therapeutics Announces CNTX-4975 Data Presentations at the 2019 American College of Rheumatology Annual Meeting and the 2019 American Academy of Physical Medicine and Rehabilitation Annual Assembly appeared first on Centrexion.
September 17, 2019
Centrexion Therapeutics Announces Completion of Patient Enrollment in VICTORY-3 Phase 3 Open-Label Clinical Trial of CNTX-4975 in Patients with Moderate-to-Severe Osteoarthritis Knee Pain
The post Centrexion Therapeutics Announces Completion of Patient Enrollment in VICTORY-3 Phase 3 Open-Label Clinical Trial of CNTX-4975 in Patients with Moderate-to-Severe Osteoarthritis Knee Pain appeared first on Centrexion.
Centrexion Frequently Asked Questions
When was Centrexion founded?
Centrexion was founded in 2013.
Who are Centrexion key executives?
Centrexion's key executives are Jeffrey B. Kindler, James N. Campbell and Randall Stevens.
How many employees does Centrexion have?
Centrexion has 27 employees.
Who are Centrexion competitors?
Competitors of Centrexion include Vectura Group, NovaBay Pharmaceuticals and Ra Pharmaceuticals.
Where is Centrexion headquarters?
Centrexion headquarters is located at 200 State St 6th Floor, Boston.
Where are Centrexion offices?
Centrexion has offices in Boston and Baltimore.
How many offices does Centrexion have?
Centrexion has 2 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies